When analyzing the third of the functional partners of ABP-PFN1, it was found that its content in the serum was almost two times higher in HNSCC patients with lymph node metastasis (T2–4N1–2M0) than that in patients without metastases (T1–3N0M0). Here, PFN1 is linked to metastatic malignant neoplasm in the lymph nodes.